Table 6.
Main reported series of ASCT as salvage treatment in HIV-positive patients with lymphoma.
| Reference | n. of pts | Median age (range) | Histology (n.of pts) | Conditioning regimen (n.of pts) | PFS* | OS* | Follow-up (range) |
|---|---|---|---|---|---|---|---|
| Gabarre (137) | 14 | 37 ys (27–53) | HL (6) DLBCL (5) BL (2) PEL (1) |
BEAM (5) Bu/Ara-C/Mel (1) TBI-based (8) |
4 pts alive in CR | 5 pts alive | 32 ms (14–49) |
| Krishnan (136) | 20 | 44 ys (11–68) | HL (2) DLBCL (10) BL (6) ALCL (2) |
CBV (28) TBI/Cy/Eto (4) |
85% | 85% | 32 ms (6–70) |
| Re (138) | 27 | 39 ys (31–59) | HL (8) DLBCL (13) BL (1) PBL (2) ALCL (2) PEL (1) |
BEAM | 76% | 75% | 44 ms (4–70) |
| Serrano (141) | 33 | 42 ys (28–61) | HL (10) DLBCL (10) BL/BLL (6) PBL (3) ALCL (3) PTCL (1) |
BEAM (27) BEAC (3) TBI-based (3) |
53% at 61 ms | 61% at 61 ms | 58 ms (2–114) |
| Balsalobre (135) | 68 | 41 ys (29–62) | HL (18) DLBCL (31) BL/BLL (8) PBL (4) ALCL (3) PTCL (3) |
BEAM and variants (65) TBI-based (3) |
56% | 61% | 32 ms (2–81) |
| Spitzer (139) | 20 | 42 ys (33–60) | HL (5) DLBCL (12) BL/BLL (3) |
Dose reduced Bu/Cy | 49% | 74% | 6 ms (1–30) |
| Alvarnas (140) | 40 | 47 ys (22–62) | HL (15) DLBCL (16) BL/BLL (7) PBL (2) |
BEAM | 80% | 82% | 25 ms (3–28) |
DLBCL: diffuse large B-cell lymphoma, BL: Burkitt lymphoma, BLL: Burkitt-like lymphoma, HL: Hodgkin lymphoma, PBL: plasmablastic lymphoma, PEL: primary effusion lymphoma, ALCL: anaplastic large cell lymphoma, PTCL: peripheral T-cell lymphoma, TBI: total Body irradiation, Cy: cyclophosphamide, Mel: melphalan, Bu: busulfan, Ara-C: cytarabine, Eto: etoposide, BEAM: BCNU, etoposide, cytarabine, melphalan, BEAC: BCNU, etoposide, cytarabine, cyclophosphamide, CBV: cyclophosphamide, BCNU, etoposide. TBI: total body irradiation, n.: number, pts: patients, ms: months, ys: years, PFS: progression free survival, OS: overall survival, CR: complete remission.
PFS and OS are reported at median follow-up unless otherwise stated